Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 100/100

Failure Rate

50.0%

2 terminated/withdrawn out of 4 trials

Success Rate

33.3%

-53.2% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1
3(75.0%)
Early Phase 1
1(25.0%)
4Total
Phase 1(3)
Early Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT05756907Phase 1Terminated

Combination of SON-1010 (IL12-FHAB) and Atezolizumab in Patients With Platinum-resistant Ovarian Cancer

Role: lead

NCT05352750Phase 1Active Not Recruiting

Phase 1 Study of SON-1010 in Adult Patients With Advanced Solid Tumors

Role: lead

NCT05435742Phase 1Terminated

SON-080 in Patients With Persistent Chemotherapy-induced Peripheral Neuropathy (CIPN)

Role: lead

NCT05408572Early Phase 1Completed

Study of SON-1010 (IL12-FHAB) in Healthy Adults

Role: lead

All 4 trials loaded